|
市場調査レポート
商品コード
1376843
非転移性前立腺がん(nmPC)市場 - 市場の洞察、疫学、市場予測:2032年Non-metastatic Prostate Cancer (nmPC) - Market Insight, Epidemiology and Market Forecast -2032 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。 |
非転移性前立腺がん(nmPC)市場 - 市場の洞察、疫学、市場予測:2032年 |
出版日: 2023年11月01日
発行: DelveInsight
ページ情報: 英文 200 Pages
納期: 1~3営業日
|
非転移性前立腺がん(nmPC)とは、前立腺とその近傍のリンパ節を超えて転移していない前立腺がんを指します。前立腺がんの限局型です。前立腺がんがこの病期で診断されるということは、がん細胞が前立腺に限局しており、周囲の組織への浸潤や骨、肺、肝臓などの遠隔臓器への転移(拡がり)をまだ起こしていないことを意味します。
非転移性前立腺がんは通常、前立腺特異抗原(PSA)血液検査、直腸指診(DRE)、前立腺生検などの検査を組み合わせて診断されます。また、前立腺内のがんの範囲や位置を評価するために、マルチパラメトリック磁気共鳴画像法(mpMRI)などの画像診断法を用いることもあります。
前立腺がんの病期分類は、疾患の範囲を決定するのに役立ちます。非転移性前立腺がんは通常、腫瘍の大きさ、近傍構造物への浸潤、リンパ節転移などの因子別、i期、II期、III期に分類されます。がんは前立腺およびその近傍に限局していると考えられます。
非転移性前立腺がんに対する治療法の選択は、患者さんの年齢、全身の健康状態、がんの侵攻性、個人の嗜好など、さまざまな要因別異なります。治療法には、積極的監視療法、手術療法、放射線療法、ホルモン療法などがあります。
主要7ヶ国地域では、米国が2022年に最大の市場規模を獲得しています。2022年、米国は32億米ドルを占めています。主要7ヶ国諸国の中で最も市場規模が小さいのはスペインで、1億5,000万米ドルです。初期治療に関しては、2022年の市場規模は手術が最も大きく、13億米ドルです。
当レポートでは、主要7ヶ国における非転移性前立腺がん(nmPC)市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2032年までの市場規模予測、および医療のアンメットニーズなどを提供しています。
There are various key players currently investigating their drugs for Non-metastatic Prostate Cancer, such as Myovant Sciences, Kangpu Biopharmaceuticals, and Candel Therapeutics etc. The details of the country and therapy-wise market size have been provided below.
The Non-metastatic Prostate Cancer report's drugs section includes an in-depth examination of marketed drugs as well as late-stage pipeline therapeutics (Phase III and Phase II) for Non-metastatic Prostate Cancer.
The drug chapters section contains useful information on various aspects of Non-metastatic Prostate Cancer clinical trials, including specific details such as the pharmacological mechanisms of the drugs involved, designations, approval status, patent information, and a comprehensive analysis of the pros and cons associated with each drug. It also includes the most recent news updates and press releases on drugs that treat Non-metastatic Prostate Cancer.
ERLEADA (apalutamide) is a next-generation oral AR inhibitor that blocks the androgen signaling pathway in prostate cancer cells. It is indicated for the treatment of patients with nmCRPC and with mCSPC. It is taken orally, once daily, with or without food. ERLEADA inhibits the growth of cancer cells in three ways: by preventing the binding of androgen to the AR, by stopping the AR from entering the cancer cells, and by preventing the AR from binding to the DNA of the cancer cell.
ORGOVYX (relugolix) is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the FDA for treating adult patients with advanced prostate cancer. As a GnRH antagonist, ORGOVYX blocks the GnRH receptor and reduces the production of testicular testosterone, a hormone known to stimulate the growth of prostate cancer. Relugolix is a nonpeptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors, thereby reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and, consequently, testosterone
CAN-2409, Candel's most advanced viral immunotherapy candidate, is a replication-defective adenovirus that delivers the herpes simplex virus thymidine kinase (HSV-tk) gene to cancer cells. HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills nearby cancer cells. The intra-tumoral administration results in the release of tumor-specific neoantigens in the microenvironment. At the same time, the adenoviral serotype 5 capsid protein elicits a strong pro-inflammatory signal in the tumor microenvironment, which is designed to create the optimal conditions to induce an individualized and specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor
Non-metastatic castration-sensitive prostate cancer is abbreviated as nmCSPC. It essentially refers to prostate cancer that has not migrated to other regions of the body and remains responsive to hormone treatment (ADT). The prevalence of mCSPC, the availability of effective therapies, evolving treatment recommendations, and the pharmaceutical sector's investment in research and development all have an impact on the market potential for nmCSPC.
With the development of cutting-edge drugs such as androgen receptor inhibitors (ARIs) such as ERLEADA (apalutamide), XTANDI (enzalutamide), and NUBEQA (darolutamide), the therapeutic landscape for nmCSPC has changed substantially. The approval of these drugs have broadened treatment choices beyond standard hormone therapy.
The traditional therapeutic method for nmCRPC patients, androgen deprivation therapy (ADT) alone until metastatic disease, is now thought to be inadequate. Several randomised Phase III clinical studies have shown considerable clinical advantages for therapies that combine ADT with apalutamide, enzalutamide, and darolutamide, including considerably improved overall survival (OS).
Metastasis-free survival (MFS) improvement in the PROSPER, SPARTAN, and ARAMIS studies supports the use of enzalutamide, apalutamide, and darolutamide in patients with nmCRPC. Because there have been no direct clinical trials comparing these three therapies, no single therapy can be established to be the best therapy in terms of clinical effectiveness or safety. In comparison to the placebo, each of these drugs has exhibited a fair safety and adverse event profile.
According to research presented at the ASCO Genitourinary Cancers Symposium (2023), it was found that patients with nmCRPC treated with NUBEQA (darolutamide) were less likely to develop metastatic disease or discontinue treatment due to adverse events than patients treated with XTANDI (enzalutamide) or ERLEADA (apalutamide).
Non-metastatic prostate cancer refers to prostate cancer that has not spread beyond the prostate gland and nearby lymph nodes. It is a localized form of prostate cancer. Prostate cancer is a highly endocrine-responsive disease. It re-lies profoundly on the androgen signaling pathway for its growth and survival.
Prostate cancer occurs when the DNA in cells in the prostate develops mutations that may disable their ability to control cell growth and division. In many cases, these mutated cells die or are attacked by the immune system. However, some mutated cells may escape the immune system and grow out of control, forming a prostate tumor
Screening is testing to find cancer in people before they have symptoms. However, It is unclear if the benefits of prostate cancer screening outweigh the risks for most men. Still, after discussing the pros and cons of screening with their doctors, some men might reasonably choose to be screened. If one of these test results is abnormal, patients will probably need a prostate biopsy to know the cancer occurrence.
Localized prostate cancer represents a paradox when left untreated; it is generally associated with a good prognosis. However, because prostate cancer is a common cause of cancer-related mortality, there is usually significant patient anxiety once the diagnosis is confirmed. All standard treatments carry risks of adverse events that might negatively impact short-, medium-, or long-term quality of life. As such, the clinical approach to managing localized prostate cancer must consider not only the disease features, such as stage, grade, and volume of cancer detected, but also patient comorbidities, life expectancy, and priorities.
The optimal management of localized prostate cancer starts with discussion by a multidisciplinary team (MDT) consisting of radiation oncologists, medical oncologists, urologists, histopathologists, radiologists, and specialist nurses. Each brings their expertise and knowledge of the patient to help determine which treatment options are appropriate for an individual.
Further details related to treatment and management are provided in the report…..
The Non-metastatic Prostate Cancer epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Total Diagnosed Prevalent Cases of Non-metastatic Prostate Cancer, Total Age-specific Cases of Non-metastatic Prostate Cancer, Total Stage-specific Cases of Non-metastatic Prostate Cancer, Total Line-wise Treated Cases of Non-metastatic Prostate Cancer covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.
In order to stay abreast of the latest trends in the market, we conduct primary research by seeking the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) who work in the relevant field. This helps us fill any gaps in data and validate our secondary research.
We have reached out to industry experts to gather insights on various aspects of Non-metastatic Prostate Cancer, including the evolving treatment landscape, patients' reliance on conventional therapies, their acceptance of therapy switching, drug uptake, and challenges related to accessibility. The experts included medical/scientific writers, professors, and researchers from prestigious universities in the US, Europe, the UK, and Japan.
Our team of analysts at DelveInsight connected with more than 10 KOLs across the 7 Major Markets (7MM). We contacted institutions such as Duke University, University of Manchester, and others. By obtaining the opinions of these experts, we gained a better understanding of the current and emerging treatment patterns in the Non-metastatic Prostate Cancer market, which will assist our clients in analyzing the overall epidemiology and market scenario.
We conduct qualitative and market intelligence analysis employing a variety of methods, including SWOT analysis and Conjoint Analysis. Strengths, weaknesses, opportunities, and threats in disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are described in the SWOT analysis. These recommendations are based on the Analyst's evaluation of the patient burden, cost analysis, and the current and emerging therapy landscape. Conjoint Analysis compares the effectiveness and safety of numerous approved and emergent drugs depending on key criteria such as frequency of administration, designation, route of administration, and order of entry. To assess the success of therapy, several factors are evaluated.
Furthermore, the drug's safety is analyzed, in which acceptability, tolerability, and adverse events are closely monitored, and it establishes a firm grasp of the side effects posed by the drugs used in the trials. Furthermore, for each therapy, the rating is based on the route of administration, sequence of entrance and designation, chance of success, and addressable patient pool. The ultimate weightage score and ranking of developing therapeutics are determined by these characteristics.
Because newly authorized drugs are often expensive, some patients escape receiving proper treatment or use off-label, less expensive prescriptions. Reimbursement plays a critical role in how innovative treatments can enter the market. The cost of the medicine, compared to the benefit it provides to patients who are being treated, sometimes determines whether or not it will be reimbursed. Regulatory status, target population size, the setting of treatment, unmet needs, the number of incremental benefit claims, and prices can all affect market access and reimbursement possibilities.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.